Finasteride and Simvastatin Interaction: What You Need to Know

Updated Jan 28, 2025

Image: HealthRX.com clinical image

Finasteride (Propecia 1 mg for hair loss, Proscar 5 mg for benign prostatic hyperplasia) is a 5-alpha reductase inhibitor. Simvastatin (Zocor) is an HMG-CoA reductase inhibitor (statin) used for cholesterol lowering. They are not chemically related and do not share a mechanism of action, but both are processed, at least in part, by the liver enzyme CYP3A4. That shared metabolic pathway is the entire basis of this interaction question.

HealthRX.com quick answer. Finasteride and simvastatin are both handled by CYP3A4, and finasteride is generally described as a weak inhibitor of that enzyme. In theory this could modestly raise simvastatin blood levels, which matters because higher simvastatin exposure raises the risk of statin-related muscle injury (myopathy and, rarely, rhabdomyolysis). No dedicated clinical trial establishing the size of this specific interaction is cited here; the FDA labels for each drug independently describe the CYP3A4 pathway and simvastatin's dose-related myopathy risk. This is a plausible, low-grade pharmacokinetic interaction, not a documented case-based one, and the practical question is whether a given patient's total risk profile (statin dose, age, kidney function, other interacting drugs) is high enough to warrant monitoring or a statin switch.

The direct answer

For most people on simvastatin 10 to 20 mg per day with no other CYP3A4-inhibiting medications and no additional muscle-injury risk factors, adding finasteride is unlikely to cause a clinically meaningful problem. For people on simvastatin 40 to 80 mg per day, or who are older, have reduced kidney function, have hypothyroidism, or are also taking another CYP3A4 inhibitor (certain antifungals, macrolide antibiotics, calcium channel blockers, or gemfibrozil), the combination deserves a specific conversation with the prescriber about dose or an alternative statin. This is a pharmacologically plausible interaction based on shared metabolism, not a well-quantified one, and a reader should not treat any specific percentage increase in simvastatin exposure attributable to finasteride as an established number.

What is actually known versus what is inferred

It helps to separate three different kinds of claims that get blended together in most consumer content on this topic.

Established by regulators. The FDA simvastatin label classifies concomitant medications by CYP3A4 inhibition strength and sets explicit rules: strong inhibitors (drugs such as itraconazole, ketoconazole, and certain macrolide antibiotics or HIV protease inhibitors) are contraindicated with simvastatin, and moderate inhibitors (such as diltiazem or verapamil) carry a defined dose ceiling (according to simvastatin's FDA-approved prescribing information). The FDA also restricted simvastatin 80 mg in 2011 to patients already stable on that dose for 12 months, based on a higher observed rate of myopathy at the highest dose. The finasteride label for Proscar states that finasteride is metabolized via CYP3A4 (according to finasteride's FDA-approved prescribing information). Note that these are archived label versions; a reader making a current prescribing decision should check the current label on DailyMed or FDA.gov, since labels are periodically revised.

Not established for this specific pair. Finasteride is commonly described in reference materials as a weak CYP3A4 inhibitor, but this article did not locate a primary pharmacokinetic study directly measuring simvastatin blood levels when co-administered with finasteride. Numeric estimates that circulate online (for example, a specific fold-increase in simvastatin AUC attributable to finasteride) should be treated as unverified until traced to a primary source. Neither the finasteride label nor the simvastatin label lists the other drug by name in its interaction tables in the versions cited above. That absence does not prove safety; weak inhibitors are often not itemized individually because their expected effect is small, not because the interaction was studied and ruled out.

Plausible but unproven. Because finasteride sits in the weak-inhibitor category by mechanism, and because simvastatin's own label demonstrates that even moderate CYP3A4 inhibition requires a dose cap, it is pharmacologically reasonable to expect finasteride to produce some small upward shift in simvastatin exposure. Whether that shift is clinically detectable in an individual patient, especially at simvastatin doses of 20 mg or below, has not been demonstrated in the material reviewed for this page.

Evidence-status interaction assessment

Question	Status	What supports it	What a clinician/pharmacist should verify
Do finasteride and simvastatin share a metabolic pathway?	Established	Both are described in their respective FDA labels as substrates of CYP3A4	Confirm current label language, since labels are revised over time
Is finasteride classified as a CYP3A4 inhibitor?	Established in pharmacology references	Widely described as a weak inhibitor in drug interaction references	Check an up-to-date interaction database (e.g., Lexicomp, Micromedex) for the current severity rating
Does finasteride meaningfully raise simvastatin blood levels in humans?	Not established here	No primary pharmacokinetic study of this specific pair was located for this article	Search PubMed/clinicaltrials.gov directly before quoting a specific fold-change
Does simvastatin dose change the stakes of any interaction?	Established	FDA label sets explicit dose caps by inhibitor strength and restricted the 80 mg dose after trial data showed a dose-related myopathy signal	Confirm the patient's current simvastatin dose and duration on that dose
Do other drugs in the regimen matter more than finasteride alone?	Established as a general statin-safety principle	FDA label lists strong/moderate inhibitors and gemfibrozil as higher-risk combinations independent of finasteride	Full medication reconciliation, including OTC and supplements, at every visit
Does timing doses apart reduce risk?	Not established / mechanistically unlikely	CYP3A4 inhibition reflects enzyme occupancy over the dosing interval rather than a moment-in-time competition	No specific verification needed; do not counsel patients that spacing doses solves the issue
Does finasteride affect warfarin?	Uncertain, case-level only	Isolated case reports exist in older literature describing potentiated anticoagulation with 5-alpha reductase inhibitors	Any patient on warfarin starting finasteride should have INR rechecked per prescriber judgment; do not rely on this page for a specific interval

Why simvastatin dose is the variable that matters most

The clinical concern with any CYP3A4 interaction involving simvastatin is muscle injury: myalgia (aching without lab abnormality), myopathy (muscle pain with a markedly elevated creatine kinase), and, rarely, rhabdomyolysis (severe muscle breakdown that can cause kidney injury). The FDA's 80 mg restriction exists because a large randomized trial comparing simvastatin 80 mg to 20 mg found a clearly higher rate of muscle toxicity at the higher dose. That regulatory action establishes, at the population level, that simvastatin's muscle risk rises with exposure. Anything that increases effective exposure, including a weak CYP3A4 inhibitor, therefore raises the same category of risk, even if the specific magnitude of finasteride's contribution has not been separately quantified. This is the reasoning basis for caution at higher simvastatin doses, not a claim that finasteride has been shown to convert a 40 mg dose into an effectively higher one.

Risk factors that compound this general concern, independent of finasteride, include:

Age 65 or older
Reduced kidney function
Uncontrolled hypothyroidism
Low body mass
Concurrent use of a stronger CYP3A4 inhibitor (certain antifungals, macrolides, some calcium channel blockers)
Concurrent gemfibrozil, which raises myopathy risk through a separate pharmacodynamic mechanism

A patient with several of these factors on simvastatin 40 mg or 80 mg is a different clinical picture than a patient on simvastatin 10 mg with none of them, even before finasteride enters the equation.

What monitoring looks like in practice

Routine, asymptomatic creatine kinase monitoring is not something current statin-safety guidance from cardiology bodies recommends for most patients; it adds cost without clear benefit when a patient has no symptoms. A more targeted approach:

Before starting or continuing both drugs

Confirm current simvastatin dose and how long the patient has been stable on it.
Ask about muscle symptoms, personal or family history of statin intolerance, kidney or thyroid disease.
Reconcile the full medication list, including anything prescribed by a different provider (this matters especially when finasteride comes from a telehealth or dermatology source and simvastatin from a primary care or cardiology source).

During treatment

New muscle aching, tenderness, or weakness, especially in the thighs, calves, or back, warrants a call to the prescriber rather than watchful waiting, particularly if it appears after either drug was started or a dose was increased.
Dark, brown, or cola-colored urine alongside muscle pain is a signal to seek prompt medical evaluation, since it can indicate myoglobin in the urine from muscle breakdown.
A creatine kinase check is reasonable if symptoms appear; it is not something to schedule automatically in an asymptomatic patient.

When to consider a different statin Switching away from simvastatin is a reasonable discussion, not a mandatory step, when the patient is on 40 mg or higher and also carries one or more of the risk factors above, or when another CYP3A4 inhibitor is already in the regimen. Statins that do not depend primarily on CYP3A4 for clearance, such as rosuvastatin (a CYP2C9 substrate) and pravastatin (largely renally eliminated, minimal CYP450 metabolism), sidestep this specific interaction pathway. Rosuvastatin has demonstrated cardiovascular event reduction in large randomized trials, including the JUPITER trial in patients with elevated inflammatory markers; the exact magnitude of benefit reported in that trial should be checked against the original publication rather than assumed from secondary summaries. Pravastatin generally produces somewhat less LDL lowering than simvastatin at comparable milligram doses, which is a tradeoff worth discussing rather than an automatic downside.

What this does not change

Finasteride's action on 5-alpha reductase and dihydrotestosterone is pharmacologically unrelated to simvastatin's cholesterol-lowering mechanism. There is no pharmacodynamic interaction here; the entire concern is pharmacokinetic. Taking simvastatin does not change how finasteride works for hair loss or BPH, and PSA suppression on finasteride is not altered by concurrent statin use. Separating the two doses by several hours has no established basis for reducing the interaction, since CYP3A4 inhibition depends on ongoing enzyme occupancy rather than a moment when the two drugs meet in the bloodstream.

When to seek urgent care

Muscle pain accompanied by dark urine, fever, or marked weakness is not something to manage by waiting for a scheduled appointment. That combination can indicate rhabdomyolysis, which can progress to kidney injury, and warrants prompt medical evaluation, including same-day contact with a prescriber or a visit to urgent or emergency care if symptoms are severe or rapidly worsening.

Frequently asked questions

Can I take finasteride with simvastatin?

Most people can, particularly at lower simvastatin doses without other interacting medications or muscle-injury risk factors. Finasteride is generally classified as a weak CYP3A4 inhibitor, the same enzyme that clears simvastatin, so a full medication review with your prescriber or pharmacist is worthwhile, especially if your simvastatin dose is 40 mg or higher.

Does finasteride raise simvastatin blood levels?

It is pharmacologically plausible, since finasteride is described as a weak CYP3A4 inhibitor and simvastatin is a CYP3A4 substrate. A specific, verified human pharmacokinetic study quantifying this exact interaction was not located for this article. Treat any specific fold-increase figure you see elsewhere as unverified until traced to its primary source.

What are the warning signs of statin-related muscle injury?

Unexplained aching, tenderness, or weakness in large muscle groups, especially if it starts or worsens after beginning or increasing a medication, and dark or cola-colored urine, which can signal muscle breakdown affecting the kidneys. Fever with muscle pain is another reason to seek prompt evaluation.

Should I switch off simvastatin if I take finasteride?

Not automatically. It becomes a reasonable conversation if you are on simvastatin 40 mg or higher, are over 65, have reduced kidney function, hypothyroidism, or are taking another CYP3A4 inhibitor or gemfibrozil. Rosuvastatin and pravastatin do not rely primarily on CYP3A4 and are commonly discussed alternatives in that situation.

Does spacing out the doses of finasteride and simvastatin reduce the risk?

There is no established mechanistic reason to expect this. CYP3A4 inhibition reflects ongoing enzyme occupancy over the dosing interval rather than a single moment of competition, so taking the two drugs at different times of day is unlikely to meaningfully change exposure.

Does this interaction affect how well finasteride works for hair loss or BPH?

No. The interaction concern is about simvastatin exposure, not finasteride's effect on 5-alpha reductase or dihydrotestosterone. Finasteride's mechanism and expected effects on hair or prostate symptoms are unrelated to simvastatin co-administration.

Do I need regular blood tests while taking both drugs?

Routine creatine kinase testing in someone without symptoms is generally not recommended by current statin-safety guidance. A baseline check is reasonable if you have additional risk factors, and testing during treatment is appropriate if you develop muscle symptoms.

References

U.S. Food and Drug Administration. Zocor (simvastatin) Prescribing Information. Consult the current label on DailyMed or FDA.gov before relying on specific dose-cap language.
U.S. Food and Drug Administration. Proscar (finasteride) Prescribing Information. Consult the current label on DailyMed or FDA.gov before relying on specific metabolism language.

A targeted PubMed and clinicaltrials.gov search for a dedicated finasteride-simvastatin pharmacokinetic interaction study did not return a clearly matching primary source at the time this article was drafted. Numeric claims about the size of this specific interaction should be verified directly against the primary literature before publication.